Literature DB >> 1864612

Genotype-phenotype correlation and germline mosaicism in DMD/BMD patients with deletions of the dystrophin gene.

A E Covone1, M Lerone, G Romeo.   

Abstract

The molecular analysis of 127 DMD/BMD patients showed that 73 of them (57%) had deletions in the dystrophin gene. Two different methods were used in this study: (a) hybridization of HindIII-digested genomic DNA with nine cDNA probes corresponding to the entire 14kb cDNA of the DMD gene; and (b) simultaneous amplification of nine exons of the DMD gene (multiplex DNA amplification) by the polymerase chain reaction (PCR). When the deletion breakpoints of the intragenic deletions were analyzed with regard to their phenotypic consequences, nine patients were found to represent exceptions to the reading-frame hypothesis. Information regarding mental development was also available for 61 of the 73 deleted patients and for 34 of the 54 non-deleted ones. The proportion of mentally retarded patients was found to be similar in the two groups (deleted, 15%; non-deleted, 18%). Finally, in one family, a junction fragment present in the patient was not found in the peripheral blood DNA of the mother but was present in the sister, thus indicating germline mosaicism in the mother.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1864612     DOI: 10.1007/bf00200919

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  31 in total

1.  Germinal mosaicism increases the recurrence risk for 'new' Duchenne muscular dystrophy mutations.

Authors:  E Bakker; H Veenema; J T Den Dunnen; C van Broeckhoven; P M Grootscholten; E J Bonten; G J van Ommen; P L Pearson
Journal:  J Med Genet       Date:  1989-09       Impact factor: 6.318

2.  A deletion hot spot in the Duchenne muscular dystrophy gene.

Authors:  M C Wapenaar; T Kievits; K A Hart; S Abbs; L A Blonden; J T den Dunnen; P M Grootscholten; E Bakker; C Verellen-Dumoulin; M Bobrow
Journal:  Genomics       Date:  1988-02       Impact factor: 5.736

Review 3.  Review and hypotheses: somatic mosaicism: observations related to clinical genetics.

Authors:  J G Hall
Journal:  Am J Hum Genet       Date:  1988-10       Impact factor: 11.025

4.  Possibilities and limitation of prenatal diagnosis and carrier determination for Duchenne and Becker muscular dystrophy using cDNA probes.

Authors:  A Speer; A W Spiegler; R Hanke; K Grade; U Giertler; J Schieck; S Forrest; K E Davies; R Neumann; R Bollmann
Journal:  J Med Genet       Date:  1989-01       Impact factor: 6.318

5.  Genomic sequencing.

Authors:  G M Church; W Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

6.  Analysis of molecular deletions with cDNA probes in patients with Duchenne and Becker muscular dystrophies.

Authors:  H Gilgenkrantz; J Chelly; M Lambert; D Récan; J C Barbot; G J van Ommen; J C Kaplan
Journal:  Genomics       Date:  1989-10       Impact factor: 5.736

7.  Gene deletions in X-linked muscular dystrophy.

Authors:  M Lindlöf; A Kiuru; H Kääriäinen; H Kalimo; H Lang; H Pihko; J Rapola; H Somer; M Somer; M L Savontaus
Journal:  Am J Hum Genet       Date:  1989-04       Impact factor: 11.025

8.  The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion.

Authors:  M Koenig; A H Beggs; M Moyer; S Scherpf; K Heindrich; T Bettecken; G Meng; C R Müller; M Lindlöf; H Kaariainen; A de la Chapellet; A Kiuru; M L Savontaus; H Gilgenkrantz; D Récan; J Chelly; J C Kaplan; A E Covone; N Archidiacono; G Romeo; S Liechti-Gailati; V Schneider; S Braga; H Moser; B T Darras; P Murphy; U Francke; J D Chen; G Morgan; M Denton; C R Greenberg; K Wrogemann; L A Blonden; M B van Paassen; G J van Ommen; L M Kunkel
Journal:  Am J Hum Genet       Date:  1989-10       Impact factor: 11.025

9.  Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history.

Authors:  M H Brooke; G M Fenichel; R C Griggs; J R Mendell; R Moxley; J P Miller; M A Province
Journal:  Muscle Nerve       Date:  1983-02       Impact factor: 3.217

10.  Alternative splicing of human dystrophin mRNA generates isoforms at the carboxy terminus.

Authors:  C A Feener; M Koenig; L M Kunkel
Journal:  Nature       Date:  1989-04-06       Impact factor: 49.962

View more
  9 in total

Review 1.  Molecular biology of neurological diseases.

Authors:  W J Cumming
Journal:  Postgrad Med J       Date:  1992-04       Impact factor: 2.401

2.  Screening Duchenne and Becker muscular dystrophy patients for deletions in 30 exons of the dystrophin gene by three-multiplex PCR.

Authors:  A E Covone; F Caroli; G Romeo
Journal:  Am J Hum Genet       Date:  1992-09       Impact factor: 11.025

3.  Patterns of deletions of the dystrophin gene in different European populations.

Authors:  G A Danieli; F Mioni; C R Müller; L Vitiello; M L Mostacciuolo; T Grimm
Journal:  Hum Genet       Date:  1993-05       Impact factor: 4.132

4.  The clinical and molecular genetic approach to Duchenne and Becker muscular dystrophy: an updated protocol.

Authors:  A J van Essen; A L Kneppers; A H van der Hout; H Scheffer; I B Ginjaar; L P ten Kate; G J van Ommen; C H Buys; E Bakker
Journal:  J Med Genet       Date:  1997-10       Impact factor: 6.318

Review 5.  A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground.

Authors:  Toshifumi Yokota; Shin'ichi Takeda; Qi-Long Lu; Terence A Partridge; Akinori Nakamura; Eric P Hoffman
Journal:  Arch Neurol       Date:  2009-01

Review 6.  Optimizing exon skipping therapies for DMD.

Authors:  T Yokota; W Duddy; T Partridge
Journal:  Acta Myol       Date:  2007-12

7.  Mutation types and aging differently affect revertant fiber expansion in dystrophic mdx and mdx52 mice.

Authors:  Yusuke Echigoya; Joshua Lee; Merryl Rodrigues; Tetsuya Nagata; Jun Tanihata; Ashkan Nozohourmehrabad; Dharminder Panesar; Bailey Miskew; Yoshitsugu Aoki; Toshifumi Yokota
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

8.  Combining Protein Expression and Molecular Data Improves Mutation Characterization of Dystrophinopathies.

Authors:  Gisela Gaina; Rolf H A M Vossen; Emilia Manole; Doina Anca Plesca; Elena Ionica
Journal:  Front Neurol       Date:  2021-12-07       Impact factor: 4.003

9.  MLPA followed by target-NGS to detect mutations in the dystrophin gene of Peruvian patients suspected of DMD/DMB.

Authors:  María Luisa Guevara-Fujita; Francia Huaman-Dianderas; Daisy Obispo; Rodrigo Sánchez; Victor Barrenechea; Diana Rojas-Málaga; Alejandro Estrada-Cuzcano; Milana Trubnykova; Mario Cornejo-Olivas; Victoria Marca; Bertha Gallardo; Milagros Dueñas-Roque; Ana Protzel; Carlos Castañeda; Hugo Abarca; Luis Celis; Jorge La Serna-Infantes; Ricardo Fujita
Journal:  Mol Genet Genomic Med       Date:  2021-07-29       Impact factor: 2.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.